Abstract
DNA-based vector systems have been widely studied as new modalities for the prevention and treatment of human diseases. As for all other medicinal products, safety is an important aspect in the evaluation of such products. In this chapter we reflect on the basic safety issues which have been raised with respect to preventive and therapeutic DNA vaccines, including insertional mutagenesis in case of chromosomal integration, possible formation of anti-DNA antibodies, induction of autoimmune responses and/or immunological tolerance. In addition, local reactions at the site of administration and adverse effects resulting from plasmid DNA spread to nontarget tissues are discussed. Most importantly, however, the benefit-risk profile of a medicinal product is crucial for a decision on providing marketing authorization or not. A product has an acceptable benefit-risk profile if the benefits of the product outweigh its risks for the treated patient.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
U.S. National Library of Medicine, National Institutes of Health, Clinical Trials database <http://clinicaltrials.gov/ct2/search>.
European Medicines Agency, EU Clinical Trials register <https://www.clinicaltrialsregister.eu/contacts.html>.
Liu MA (2011) DNA vaccines: an historical perspective and view to the future. Immunol Rev 239:62–84
Kendall M (2006) Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 24:4651–4656
Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252
Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86–89
Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges. J Immunol 175:633–639
Feltquate DM et al (1997) Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158:2278–2284
Ferraro B et al (2011) Clinical applications of DNA vaccines: current progress. Clin Infect Dis 53:296–302
Otten G et al (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22:2489–2493
Satkauskas S et al (2001) Slow accumulation of plasmid in muscle cells: supporting evidence for a mechanism of DNA uptake by receptor-mediated endocytosis. Mol Ther 4:317–323
Barry ME et al (1999) Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum Gene Ther 10:2461–2480
Dale CJ et al (2006) Prime-boost strategies in DNA vaccines. Methods Mol Med 127:171–197
Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927–974
Schüle S et al (2010) Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53:30–37
/120/EC, The Commission of the European communities. Off J Eur Comm L 242 15(9)2009, p. 3–12. <http://ec.europa.eu/health/files/eudralex/vol-1/dir_2009_120/dir_2009_120_en.pdf>.
/83/EC. The European Parliament and the Council of the European Union. Off. J Eur Comm. L311, 67–126 (2001). <http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_cons2009/2001_83_cons2009_en.pdf>.
Gaspar HB et al (2004) Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364:2181–2187
Cavazzana-Calvo M et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–672
Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M (2010) 20 years of gene therapy for SCID. Nat Immunol 11:457–460
Wang Z et al (2004) Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 11:711–721
Ledwith BJ et al (2000) Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 43:258–272
Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9:776–788
Faurez F et al (2010) Biosafety of DNA vaccines: new generation of DNA vectors and current knowledge on the fate of plasmids after injection. Vaccine 28:3888–3895
WHO. World Health Organization: Guidelines for assuring the quality and nonclinical safety evaluation of DNA vaccines; WHO Technical Report Series No 941, 2007, Annex 1. <http://www.who.int/biologicals/publications/trs/areas/vaccines/dna/Annex%201_DNA%20vaccines.pdf>.
Food and Drug Administration: Guidance for Industry: Considerations for plasmid DNA vaccines for infectious disease indications, 2007 < http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm074770.htm >.
Committee for the Medicinal Product for Human Use (CHMP): Guideline on safety and efficacy follow-up - risk management of advanced therapy medicinal products (EMEA/149995/2008) <http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500006326.pdf>.
Committee for Medicinal Products for Human Use CHMP/GTWP/60436/07. Follow-up of patients administered with gene therapy medicinal products (Draft). EMEA, London. 2008. <http://www.emea.europa.eu/pdfs/human/genetherapy/6043607endraft.pdf>.
Manam S et al (2000) Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43:273–281
Bureau MF et al (2004) Intramuscular plasmid DNA electrotransfer: biodistribution and degradation. Biochim Biophys Acta 1676:138–148
Gallot D et al (2002) Systemic diffusion including germ cells after plasmidic in utero gene transfer in the rat. Fetal Diagn Ther 17:157–162
Schalk JA et al (2006) Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin 2:45–53
/2005. EMEA/CHMP: Guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectors <http://www.emea.europa.eu/pdfs/human/swp/27397405enfin.pdf>.
Donnelly JJ et al (1997) DNA vaccines. Annu Rev Immunol 15:617–648
Mor G, Eliza M (2001) Plasmid DNA vaccines. Immunology, tolerance, and autoimmunity. Mol Biotechnol 19:245–250
Pavlovic M et al (2010) Pathogenic and epiphenomenal anti-DNA antibodies in SLE. Autoimmune Dis 2011:462841
Manson JJ, Isenberg DA (2006) The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus. Expert Rev Clin Immunol 2:377–385
Isenberg DA et al (2007) Fifty years of anti-ds DNA antibodies: are we approaching journey’s end? Rheumatology (Oxford) 46:1052–1056
Ichino M et al (1999) Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. J Immunol 162:3814–3818
Fioretti D et al (2010) DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010:174378
Mor G et al (1996) Induction of neonatal tolerance by plasmid DNA vaccination of mice. J Clin Invest 98:2700–2705
van Drunen Littel-van den Hurk S, Hannaman D (2010) Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 9, 503–517
Dean HJ (2005) Epidermal delivery of protein and DNA vaccines. Expert Opin Drug Deliv 2:227–236
Anliker B, Longhurst S, Buchholz CJ (2010) Environmental risk assessment for medicinal products containing genetically modified organisms. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53:52–57
ERA. Committee for the Medicinal Product for Human Use (CHMP). Guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal products. Doc. Ref. EMEA/CHMP/GTWP/125491/2006. EMEA, London, 2008. < >.
Droge M, Puhler A, Selbitschka W (1998) Horizontal gene transfer as a biosafety issue: a natural phenomenon of public concern. J Biotechnol 64:75–90
14. European Pharmacopeia, 6th Edition, Supplement 6.3. Chapter 5.14. Gene Transfer Medicinal Products for Human Use. 01/2008:54100, correct 6.0.
Degryse E (1991) Stability of a host-vector system based on complementation of an essential gene in Escherichia coli. J Biotechnol 18:29–39
Mairhofer J et al (2008) A novel antibiotic free plasmid selection system: advances in safe and efficient DNA therapy. Biotechnol J 3:83–89
Cranenburgh RM et al (2001) Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res 29:e26
Garmory HS et al (2005) Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium. Infect Immun 73:2005–2011
Williams SG et al (1998) Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26:2120–2124
Hanke T, McMichael AJ (2000) Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6:951–955
Hanke T et al (2002) Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21:108–114
Darquet AM et al (1997) A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther 4:1341–1349
Kay MA, He CY, Chen ZY (2010) A robust system for production of minicircle DNA vectors. Nat Biotechnol 28:1287–1289
Schirmbeck R et al (2001) Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. J Mol Med (Berl) 79:343–350
Lopez-Fuertes L et al (2002) DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21:247–257
Stacey KJ, Sweet MJ, Hume DA (1996) Macrophages ingest and are activated by bacterial DNA. J Immunol 157:2116–2122
Krieg AM et al (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549
Jakob T et al (1998) Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161:3042–3049
Landrigan A, Wong MT, Utz PJ (2011) CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism. J Immunol 187:3033–3043
Sato Y et al (1996) Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352–354
Lindau D et al (2011) Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus. Eur J Immunol 41:669–681
Yasuda K et al (2009) Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J Immunol 183:3109–3117
Ada G, Ramshaw I (2003) DNA vaccination. Expert Opin Emerg Drugs 8:27–35
Yamada H et al (2002) Effect of suppressive DNA on CpG-induced immune activation. J Immunol 169:5590–5594
Krieg AM et al (1998) Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A 95:12631–12636
Tolmachov O (2009) Designing plasmid vectors. Methods Mol Biol 542:117–129
Wooddell CI et al (2011) Muscle damage after delivery of naked plasmid DNA into skeletal muscles is batch dependent. Hum Gene Ther 22:225–235
Magalhaes PO et al (2007) Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci 10:388–404
Schleef M et al (2010) Production of non viral DNA vectors. Curr Gene Ther 10:487–507
MacGregor RR et al (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178:92–100
Lu S, Wang S, Grimes-Serrano JM (2008) Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 7:175–191
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Langer, B., Renner, M., Scherer, J., Schüle, S., Cichutek, K. (2013). Safety Assessment of Biolistic DNA Vaccination. In: Sudowe, S., Reske-Kunz, A. (eds) Biolistic DNA Delivery. Methods in Molecular Biology, vol 940. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-110-3_27
Download citation
DOI: https://doi.org/10.1007/978-1-62703-110-3_27
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-109-7
Online ISBN: 978-1-62703-110-3
eBook Packages: Springer Protocols